Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study

PURPOSE: Anlotinib is a novel oral small-molecule multi-target tyrosine kinase inhibitor that has been approved for treating non-small cell lung cancer. However, its efficacy and safety among patients with advanced gynecological cancer have not been comprehensively evaluated. We conducted this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Xinyi, Qiu, Shanhu, Wu, Xia, Chen, Sizhen, Chen, Xiaoxiang, Zhang, Bei, He, Aiqin, Xu, Yun, Wang, Jianqing, Gao, Yingchun, Xu, Xizhong, Sun, Li, Zhang, Yang, Xiang, Libing, Zhou, Jundong, Guan, Qun, Zhu, Yanling, Liu, Haiyan, Xu, Hao, Zhou, Ying, Chen, Bingwei, Shen, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332361/
https://www.ncbi.nlm.nih.gov/pubmed/37435095
http://dx.doi.org/10.2147/DDDT.S408304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332361/
https://www.ncbi.nlm.nih.gov/pubmed/37435095
http://dx.doi.org/10.2147/DDDT.S408304

Ejemplares similares